Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...190191192193194195196197198199200...208209»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) -  Jan 22, 2019   
    P1,  N=99, Active, not recruiting, 
    Completed --> Terminated; The applicant decided to close the study Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Sep 2017 --> Mar 2019
  • ||||||||||  SHR7390 / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / Elevar Therapeutics, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  SHR7390-I-102-AST: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 18, 2019   
    P1,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Jul 2019
  • ||||||||||  SHR7390 / Jiangsu Hengrui Pharma
    Trial primary completion date:  Phase I Study of SHR7390 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 15, 2019   
    P1,  N=60, Recruiting, 
    Trial primary completion date: Apr 2019 --> Oct 2019 Trial primary completion date: Dec 2018 --> Apr 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial primary completion date, Platinum resistant:  Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer (clinicaltrials.gov) -  Jan 15, 2019   
    P2,  N=35, Active, not recruiting, 
    Trial primary completion date: Dec 2018 --> Apr 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Dec 2017
  • ||||||||||  New P1/2 trial, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker:  FUSCC Refractory TNBC Umbrella (FUTURE) (clinicaltrials.gov) -  Jan 15, 2019   
    P1/2,  N=140, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion date, Trial initiation date, Trial primary completion date:  TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma?RCT (clinicaltrials.gov) -  Jan 8, 2019   
    P1/2,  N=202, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Nov 2020 --> Jul 2022 | Initiation date: Nov 2018 --> Feb 2019 | Trial primary completion date: May 2020 --> Feb 2022
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Enrollment change:  Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) -  Jan 4, 2019   
    P1/2,  N=194, Recruiting, 
    Trial completion date: Nov 2020 --> Jul 2022 | Initiation date: Nov 2018 --> Feb 2019 | Trial primary completion date: May 2020 --> Feb 2022 N=40 --> 194
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients (clinicaltrials.gov) -  Dec 31, 2018   
    P1,  N=37, Active, not recruiting, 
    N=40 --> 194 Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Real-world evidence, Real-world:  A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma (clinicaltrials.gov) -  Dec 21, 2018   
    P=N/A,  N=270, Active, not recruiting, 
    Trial primary completion date: Jun 2020 --> Jul 2021 Not yet recruiting --> Active, not recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) -  Dec 20, 2018   
    P1,  N=45, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | Trial completion date: Apr 2017 --> Dec 2019 | Trial primary completion date: Dec 2016 --> Aug 2019
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects (clinicaltrials.gov) -  Dec 19, 2018   
    P1,  N=20, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial completion date: Apr 2017 --> Dec 2019 | Trial primary completion date: Dec 2016 --> Aug 2019 Recruiting --> Active, not recruiting | Trial completion date: Apr 2018 --> Aug 2019 | Trial primary completion date: Feb 2018 --> Apr 2019
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
    Enrollment open:  SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery (clinicaltrials.gov) -  Dec 19, 2018   
    P=N/A,  N=45, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Apr 2018 --> Aug 2019 | Trial primary completion date: Feb 2018 --> Apr 2019 Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Update on multikinase inhibitor therapy for differentiated thyroid cancer. (Pubmed Central) -  Dec 16, 2018   
    Selective kinase inhibitors, including dabrafenib, vemurafenib, selumetinib and gefitinib, offer a more targeted approach and have also been studied in phase II clinical trials. While the emergence of these treatments has changed the landscape of management of advanced thyroid cancer, clinical challenges remain, and there are many areas of ongoing research.
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date:  A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Dec 3, 2018   
    P1,  N=30, Active, not recruiting, 
    While the emergence of these treatments has changed the landscape of management of advanced thyroid cancer, clinical challenges remain, and there are many areas of ongoing research. Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019
  • ||||||||||  HTI-1090 / Jiangsu Hengrui Pharma
    Enrollment closed, Enrollment change:  A Trial of HTI-1090 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 29, 2018   
    P1,  N=18, Active, not recruiting, 
    Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Jun 2018 --> Mar 2019 Recruiting --> Active, not recruiting | N=30 --> 18